Part 1 of this article, which
appeared in last month’s issue of ONCOLOGY, summarized the outcome of major phase III trials in cervical and
vulvar cancer. This part will provide the outcome of phase III trials in uterine
and ovarian cancer.
Endometrial cancer is the most common female genital tract
cancer in the United States. The majority of cases are confined to the uterus.
Treatment of organ-confined uterine cancer usually comprises total abdominal
hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO). In 1988, clinical
staging of endometrial cancer was replaced with surgical staging because of
inaccuracies associated with clinical staging. Over the past several decades, we
have learned more about the risk factors associated with the recurrence of
endometrial cancer. In recent years, few prospective phase III randomized
studies have been conducted in patients with endometrial carcinoma to answer
questions regarding the best management of these patients.
• GOG-33This Gynecologic Oncology Group (GOG) study
conducted by Creasman et al enrolled 621 patients with stage I/II cancer of the
endometrium. All patients underwent TAH/BSO, selective pelvic and para-aortic
lymphadenectomy, and peritoneal cytology. The depth of myometrial invasion and
grade of tumor were the most important factors predicting pelvic node and para-aortic
node metastases (Table 1).
Before 1988, endometrial cancer was clinically staged. However,
Creasman et al showed that, when a comprehensive staging procedure is performed,
22% of clinical stage I patients have disease outside the uterus. As a result,
the International Federation of Gynecology and Obstetrics (FIGO) mandated that
this disease be staged surgically.
The requirement for lymph node assessment has been the subject
of considerable debate. To different practitioners, this assessment may imply
observation, palpation, sampling, or dissection. GOG findings confirmed that
fewer than 10% of patients with nodal metastases have grossly positive nodes.
Therefore, visualization and palpation are inadequate to exclude lymph node
involvement. Pelvic lymph node dissection should be performed via multiple-sites
because retrospective evidence indicates that adequate pelvic lymph node
dissection may improve overall survival.[2,3]
• Risk GroupsIn general, patients can be divided into one of
three categories of risk for developing recurrent and metastatic disease: low
risk, intermediate risk, and high risk. When the patient’s tumor is confined
to the uterus, the primary risk factors are tumor grade, tumor histology, and
depth of invasion. Depending on the individual patient risk factors,
organ-confined endometrial cancer can be classified as either low risk (grade
1/2, endometrial invasion only, excluding clear cell and papillary serous cases)
or intermediate risk (grade 1-3, inner/middle myometrial invasion). Patients
at high risk have cervical involvement and tumor spread beyond the uterus.
Radiation is often administered to women at risk for
extrauterine spread when the status of the lymph nodes is unknown. However, the
adoption of surgical staging has led to questions regarding the role of pelvic
radiotherapy in patients with disease confined to the uterus.
Adjuvant Treatment of
• GOG-99Roberts et al evaluated surgery vs surgery plus
adjuvant radiotherapy in patients with intermediate-risk (stage IB, IC, and
occult stage II) endometrial cancer; clear cell and serous carcinomas were
excluded. All patients underwent complete surgical staging with pelvic and
para-aortic lymph node dissection and peritoneal cytology. Patients with
intermediate-risk, surgical stage I disease were then randomized to either no
further therapy or 50.4-Gy pelvic irradiation.
A preliminary report of this study showed that the pelvic
recurrence rate was 12% without radiotherapy vs 1.7% with radiotherapy.
Two-thirds of the pelvic recurrences were in the vagina alone (15/22, 68% of all
recurrences in the surgery-alone arm, as well as the only failure among patients
receiving radiation). Although the disease-free survival rate significantly
favored the radiotherapy arm93.7% vs 84.7%, respectively (P = .04)there
was no significant difference in the overall survival rate at 3 years (89% vs
96%, P = .09). This study will require further follow-up before a
final analysis of overall survival can be performed.
The intermediate-risk group represents a heterogeneous group of
patients. The patient population accrued in this study was much more favorable
than anticipated (< 18% had outer one-third myometrial invasion, and 81.6%
had grade 1 and 2 tumors), leaving the study insufficiently powered to observe
survival differences. Therefore, the role of pelvic irradiation in patients with
deep myometrial invasion and high-grade tumor is still unclear and needs to be
Since the main benefit of pelvic irradiation is a decrease in
the vaginal recurrence rate, it could be argued that women with
intermediate-risk tumors, especially those who are well staged, should receive
adjunctive vaginal vault radiation therapy only, which has fewer side effects.
Several retrospective studies have demonstrated excellent outcomes with this
approach.[5-8] Because of increased vaginal sequelae, treatment of the entire
length of the vagina is usually not recommended.
• NCIC trialAn ongoing trial being conducted by the National
Cancer Institute of Canada (NCIC) clinical trial group is similar to GOG-99. The
accrual goal is approximately 400 patients. The results of this study will help
clinicians make appropriate therapeutic decisions for this patient population.
• RTOG-99-05Recently, the Radiation Therapy Oncology Group (RTOG)
initiated a phase III study (99-05) of adjuvant postoperative irradiation
with or without cisplatin and paclitaxel following TAH/BSO in patients with
endometrial cancer. Selection criteria include uterine-confined cancer, but this
population (with stage IC and IIA/B disease) is at higher risk of disease
recurrence than were women enrolled in GOG-99. Regional lymph node sampling is
not necessary for this study population.
• Other Trials in Organ-Confined DiseaseTable 2 compares the
parameters of GOG-99 with those in two other randomized trials of clinically
organ-confined endometrial cancer.[4,9,10] In 1980, Aalders et al published a
report on a randomized trial of primary surgery and vaginal brachytherapy with
and without additional external-beam radiation in patients with endometrial
cancer. As expected, a significant reduction in vaginal and pelvic recurrences
was observed in the group receiving adjuvant radiotherapy (1.9% vs 6.9%).
However, the overall 5-year survival did not improve. In subset analysis, those
with grade 3 lesions and > 50% myometrial invasion showed a significant
increase in survival. Pelvic node dissection was not performed in this study.
In most European countries, lymphadenectomy is not considered a
standard procedure for stage I endometrial cancer. Recently, the Dutch
Postoperative Radiation Therapy in Endometrial Cancer (PORTEC) study group
investigated whether postoperative pelvic irradiation improved locoregional
control and survival in patients with stage I endometrial cancer. The 715
patients in the intermediate-risk group were randomized to pelvic radiotherapy
(46 Gy) or no further treatment, and pelvic node dissection was not performed.
The 5-year locoregional recurrence rates were 4% in the radiotherapy group and
14% in the control group, but there was no impact on overall survival. The
majority of recurrences (73%) were restricted to the vagina. As expected, the
incidence of late complications was higher in the radiotherapy group (25% vs
6%), although most were grade 1.
The results of both the Aalders and PORTEC trials[9,10] are
based on clinically staged patients and may not be relevant for surgically
staged patients. Another Dutch trial in which lymphadenectomy is being compared
to radiotherapy in high-risk endometrial cancer has recently been initiated, and
the results of that trial will clarify the future role of lymphadenectomy in
1. Creasman WT, Morrow CP, Bundy BN, et al: Surgical pathologic
spread patterns of endometrial cancer: A Gynecologic Oncology Group study.
Cancer 60(8 suppl):2035-2041, 1987.
2. Kilgore LC, Partridge EE, Alvarez RD, et al: Adenocarcinoma
of the endometrium: Survival comparisons of patients with and without pelvic
node sampling. Gynecol Oncol 56:29-33, 1995.
3. Trimble EL, Kosary C, Park RC: Lymph node sampling and
survival in endometrial cancer. Gynecol Oncol 71:340-343, 1998.
4. Roberts J, Brunetto V, Keys H, et al: A phase III randomized
study of surgery vs surgery plus adjunctive radiation therapy in
intermediate-risk endometrial adenocarcinoma (GOG no. 99). Gynecol Oncol 68:135,
5. Petereit DG, Tannehill SP, Grocen EA, et al: Outpatient
vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer
6. Anderson JM, Stea B, Hallum AV, et al: High-dose rate
postoperative vaginal cuff irradiation alone for stage IB and IC endometrial
cancer. Int J Radiat Oncol Biol Phys 46:417-425, 2000.
7. Eltabbakh GH, Piver MS, Hempling RE, et al: Excellent
long-term survival and absence of vaginal recurrences in 332 patients with
low-risk stage I endometrial adenocarcinoma treated with hysterectomy and
vaginal brachytherapy without formal staging lymph node sampling: Report of a
prospective trial. Int J Radiat Oncol Biol Phys 38:373-380, 1997.
8. Chadha M, Nanavati PJ, Liu P, et al: Patterns of failure in
endometrial carcinoma stage IB grade 3 and IC patients treated with
postoperative vaginal vault brachytherapy. Gynecol Oncol 75:103-107, 1999.
9. Aalders J, Abeler V, Kolstad P, et al: Postoperative external
irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical
and histopathologic study of 540 patients. Obstet Gynecol 56:419-427, 1980.
10. Creutzberg CL, van Putten WL, Koper PC, et al: Surgery and
postoperative radiotherapy vs surgery alone for patients with stage I
endometrial carcinoma: Multicenter randomized trial. PORTEC Study Group
Postoperative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404-1411,
11. Axelrod J, Bandy B, Roy T, et al: Advanced endometrial
carcinoma (EC) treated with whole abdominal irradiation (WAI): A Gynecologic
Oncology Group (GOG) study. Gynecol Oncol 56:1335-136, 1995.
12. Thigpen JT, Buchsbaum HJ, Mangan C, et al: Phase II trial of
adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A
Gynecologic Oncology Group study. Cancer Treat Rep 63:21-27, 1979.
13. Thigpen JT, Blessing JA, Homesley J, et al: Phase II trial
of cisplatin as first-line chemotherapy in patients with advanced and recurrent
endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol
14. Morrow CP, Bundy BN, Homesley HD, et al: Doxorubicin as an
adjuvant following surgery and radiation therapy in patients with high-risk
endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group
study. Gynecol Oncol 36:166-171, 1990.
15. Sutton GP, Blessing JA, Rosenheim N, et al: Phase II trial
of ifosfamide and mesna in mixed mesodermal tumor of the uterus (a Gynecologic
Oncology Group study). Am J Obstet Gynecol 161:309-312, 1989.
16. Omura GA, Major FJ, Blessing JA, et al: A randomized study
of adriamycin with and with dimethyl triazenoimidazole carboxamide in advanced
uterine sarcomas. Cancer 52:626-632, 1983.
17. Scribner DR Jr, Walker JL: Low-grade endometrial stromal
sarcoma preoperative treatment with Depo-Lupron and Mecane. Gynecol Oncol
18. Maluf FC, Sabbatini P, Schwartz L, et al: Endometrial
stromal sarcoma: Objective response to letrozole. Gynecol Oncol 82:384-388,
19. Omura GA, Blessing JA, Major F, et al: A randomized clinical
trial of adjuvant adriamycin in uterine sarcoma: A Gynecologic Oncology Group
trial. J Clin Oncol 3:1240-1245, 1985.
20. Young RC, Knapp RC, Fuks Z, et al: Cancer of the ovary, in
Devita VT Jr, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of
Oncology, 2nd ed, pp 1083. New York, J.B. Lippincott, 1985.
21. Richardson GS, Scully RE, Nikrui N, et al: Common epithelial
cancer of the ovary. N Engl J Med 312: 474-483, 1985.
22. Buchsbaum HJ, Brady MF, Delgado G, et al: Surgical staging
of carcinoma of the ovaries. Surg Gynecol Obstet 169:226-232, 1989.
23. Hreshchyshyn MM, Park RC, Blessing JA, et al: The role of
adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 138:139-145,
24. Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy
in stage I and stage II epithelial ovarian cancer. Results of two prospective
trials. N Engl J Med 322:1021-1027, 1990.
25. Young RC, Brady MF, Nieberg RM, et al: Randomized clinical
trial of adjuvant treatment of women with early (FIGO 1 high-risk) ovarian
cancer GOG #95 (abstract 1376). Proc Am Soc Clin Oncol 18:357a, 1999.
26. Bolis G, Columbo N, Pecorelli S, et al: Adjuvant treatment
for early epithelial ovarian cancer: Results two randomized trials comparing
cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol
27. Vergote IB, Trimbos BJ, Guthrie D, et al: Results of a
randomized trial in 923 patients with high-risk ovarian cancer, comparing
adjuvant chemotherapy with no further treatment following surgery (abstract
802). Proc Am Soc Clin Oncol 20(part I):201a, 2001.
28. Townsend R, Glassburn JR, Brady LW, et al: Whole abdominal
irradiation for carcinoma of the ovary. Cancer Clin Trials 2:351-358, 1979.
29. Omura GA, Morrow CP, Blessing JA, et al: A randomized
comparison of melphalan versus melphalan plus hexamethylmelamine versus
adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51:783-789, 1983.
30. Omura GA, Blessing JA, Ehrlich CE, et al: A randomized trial
of cyclophosphamide and doxorubicin with or without cisplatin in advanced
ovarian carcinoma: A Gynecologic Oncology Group study. Cancer 57:1725-1730,
31. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up
and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic
Oncology Group experience. J Clin Oncol 9:1138-1150, 1991.
32. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of
cyclophosphamide plus cisplatin with or without doxorubicin in ovarian
carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:457-465, 1989.
33. The Ovarian Cancer Meta-Analysis Project: Cyclophosphamide
plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy
of ovarian carcinoma: A Meta-analysis. J Clin Oncol 9:1668-1674, 1991.
34. Vermorken JB, Harper PG, Buyse M: The role of anthracyclines
in epithelial ovarian cancer. Ann Oncol 10(suppl 1):43-50, 1999.
35. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A
unique antineoplastic agent with significant activity in advanced ovarian
epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
36. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide
and cisplatin compared with paclitaxel and cisplatin in patients with stage III
and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
37. Stuart G, Bertelsen K, Mangioni C, et al: Updated analysis
shows a highly significant improved overall survival (OS) for
cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature
results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial
(abstract 1394). Proc Am Soc Clin Oncol 17:361a, 1998.
38. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized
study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients
with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group
study. J Clin Oncol 18:106-115, 2000.
39. Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III
study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO/PAC) in
optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group
trial (GOG 158) (abstract 1373). Proc Am Soc Clin Oncol 18:356a, 1999.
40. DuBois A, Lueck HJ, Meier W, et al: Cisplatin/paclitaxel vs
carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft
Gynaekologische Onkologie (AGO) study group trial (abstract 1374). Proc Am Soc
Clin Oncol 18:356a, 1999.
41. Vasey P: Preliminary results of the SCOTROC trial: A phase
III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as
first-line chemotherapy in stage Ic-IV epithelial ovarian cancer (EOC) (abstract
804). Proc Am Soc Clin Oncol 20(part 1):202a, 2001.
42. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal
cisplatin plus intravenous cyclophosphamide versus intravenous cyclophosphamide
for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996.
43. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of
standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose
carboplatin followed by intravenous, paclitaxel and interperitoneal cisplatin in
small-volume stage III ovarian carcinoma: An intergroup study of GOG, SWOG, ECOG.
J Clin Oncol 19:1001-1007, 2001.